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Lehigh Valley Health Network, Allentown, PA
PURPOSE
This study will evaluate the management of patients diagnosed with HIV in an 
outpatient infectious diseases practice compared to evidence based guidelines. 
The 2018 guidelines from the International Antiviral Society (IAS) recognize 
three treatment regimens as “Recommended Initial Regimens for Most People 
with HIV.” These are listed below. Demographic information of this patient 
population will be collected to determine which factors, if any, are significantly 
different for patients on less strongly recommended antiretroviral medications. 
The percentage of patients who received first line recommended antiretroviral 
regimens will be reported to assess the adherence with current guidelines. 
Rates of increased viral load above 200 HIV RNA copies/mL and CD4 cell 
counts below 200 cells/mm3 will be characterized and analyzed for this patient 
population. A qualitative analysis will be completed to identify the rationale 
behind the initiation of each patient’s antiretroviral regimen. These described 
contraindications will be compared with the IAS guideline recommendations to 
act as an objective measure for appropriateness of care. Percentage of patients 
who received recommended vaccines will also be evaluated as patients with 
HIV are at an increased risk for vaccine preventable diseases due to the nature 
of immunosuppression.
PREFERRED ANTIRETROVIRAL REGIMENS 
FOR THE TREATMENT OF HIV
Based on the International Antiviral Society 2018 guideline recommendations
Available in a single pill formulation that contains an integrase inhibitor
Listed in alphabetical order by generic name of the integrase inhibitor 
component:
•  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide fumarate)
•  Triumeq (dolutegravir/abacavir/lamivudine) 
•  Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate) 
PRIMARY OBJECTIVE
Determine if there is a difference in demographic information associated with 
patient populations on certain treatment regimens for HIV.
SECONDARY OBJECTIVES 
•  Calculate the percentage of patients at this outpatient infectious diseases 
clinic whom were receiving first line recommended medications as of their 
most recent office visit on or before June 30th, 2018
•  Of those patients not on first line recommended regimens, determine  
the various contraindications to first-line recommended therapy  
(Qualitative analysis)
•  Characterize the distribution of most recent CD4 cell counts of all patients
•  Calculate the percentage of patients with undetectable viral load
•  Compare the viral loads between patients on various regimens
•  Compare the CD4 cell counts between patients on various regimens
•  Calculate the percentage of patients who have received each of the 
recommended vaccinations according to ACIP guidelines 
METHODS
Retrospective chart review utilizing EPIC electronic medical record of patients 
who are:
•  HIV positive 
•  Managed at LVPG outpatient infectious diseases clinic
Charts will be reviewed for antiretroviral regimen, vaccination history, and 
laboratory values using clinician notes, prescription lists, and medication 
administration records between February 1, 2015 and June 30, 2018.
INCLUSION CRITERIA
Inclusion in the study will be limited to a maximum of 100 patients. If more 
than 100 patients are eligible for inclusion, the 100 patients with appointment 
dates chronologically closest to June 30, 2018 will be included in the analysis.
•  Age older than 18 years
•  Diagnosis of HIV-1 
•  Attended appointment at least once between July 1, 2017 and June 30, 2018
DEMOGRAPHIC DATA TO BE COLLECTED
Age Hepatitis B Virus (HBV)
Gender Hepatitis C Virus (HCV)
Race Type 1 Diabetes Mellitus







Atherosclerotic Cardiovascular Disease (ASCVD)
Tuberculosis (TB)
Time since  
HIV Diagnosis
Chronic Lung Disease (CLD)
History of Transplant Surgery
Substance Use History of Splenectomy
IMMUNIZATION RECOMMENDATIONS
Recommend the administration of vaccines at the same schedules in all 
individuals regardless of CD4 count except for certain live virus vaccines 
Based on the Advisory Committee on Immunization Practices (ACIP) Adult 
Immunization Recommendations.
Live viruses that should be avoided when the CD4 count is ≤ 200 cells/mm3
•  Mumps/measles/rubella vaccine
•  Varicella (chicken pox) vaccine
•  Herpes zoster vaccine
ASSESSED VACCINATIONS
•  Influenza 
•  Pneumococcal conjugate
•  Pneumococcal polysaccharide 
•  Tetanus toxoid/diphtheria/pertussis
•  Human Papilloma Virus
•  Varicella 
•  Hepatitis A 
•  Hepatitis B
•  Meningococcal
•  Mumps/measles/rubella
•  Herpes Zoster Virus
STATISTICAL ANALYSIS
Descriptive statistics for the sample as a whole will be calculated and 
presented. 
Statistical comparisons between the demographic variables between groups, 
based on the various treatment regimens, will then be completed. 
•  Chi-square Test of Independence will be used for categorical variables
   If > 20% of the expected cell counts are found to be < 5, the Fisher’s 
Exact Test will alternatively be used
•  ANOVA will be used to compare continuous variables between groups
   If the distribution of variables in any of the groups is skewed, the Kruskal-
Wallis Test will alternatively be used
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